Dr. Rutika Mehta
Claim this profileMoffitt Cancer Center
Studies Adenocarcinoma
Studies Esophageal Cancer
12 reported clinical trials
29 drugs studied
Area of expertise
1Adenocarcinoma
Stage IV
Stage III
HER2 positive
2Esophageal Cancer
Stage IV
Stage III
PALB2 positive
Affiliated Hospitals
Clinical Trials Rutika Mehta is currently running
OBT076
for Advanced Cancer
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
Tele-Resistance Training
for Gastrointestinal Cancer
The purpose of the study is to evaluate a tele-resistance training exercise program for individuals undergoing chemotherapy for advanced upper gastrointestinal cancer.
Recruiting1 award Phase 1 & 2
More about Rutika Mehta
Clinical Trial Related5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rutika Mehta has experience with
- Pembrolizumab
- Oxaliplatin
- Bevacizumab
- Niraparib
- SRF617
- Nivolumab
Breakdown of trials Rutika Mehta has run
Adenocarcinoma
Esophageal Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rutika Mehta specialize in?
Rutika Mehta focuses on Adenocarcinoma and Esophageal Cancer. In particular, much of their work with Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Rutika Mehta currently recruiting for clinical trials?
Yes, Rutika Mehta is currently recruiting for 4 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Rutika Mehta has studied deeply?
Yes, Rutika Mehta has studied treatments such as Pembrolizumab, Oxaliplatin, Bevacizumab.
What is the best way to schedule an appointment with Rutika Mehta?
Apply for one of the trials that Rutika Mehta is conducting.
What is the office address of Rutika Mehta?
The office of Rutika Mehta is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.